Ultragenyx Pharmaceutical (RARE) Receives Coverage Optimism Rating of 0.15
News articles about Ultragenyx Pharmaceutical (NASDAQ:RARE) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ultragenyx Pharmaceutical earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.298574808933 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- CRY Opens Wallet, LLY’s JUNIPER Flops, MDXG Catches Eyes … – Nasdaq (nasdaq.com)
- Ultragenyx Pharma (RARE) Says FDA Accepts Burosumab BLA; Sets 04/17/18 PDUFA Date – StreetInsider.com (streetinsider.com)
- Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application (finance.yahoo.com)
- Ultragenyx Pharmaceutical Inc. (RARE) PT Raised to $71.00 at Morgan Stanley (americanbankingnews.com)
- Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 4, 2017 (finance.yahoo.com)
A number of equities analysts recently weighed in on RARE shares. BidaskClub raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Cowen and Company reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, June 29th. Stifel Nicolaus reaffirmed a “buy” rating and set a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 30th. Finally, Zacks Investment Research cut shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $71.94.
Ultragenyx Pharmaceutical (RARE) opened at 54.01 on Wednesday. The firm’s market capitalization is $2.29 billion. The firm has a 50-day moving average of $53.50 and a 200-day moving average of $59.83. Ultragenyx Pharmaceutical has a 1-year low of $49.56 and a 1-year high of $91.35.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.73) by $0.01. During the same quarter last year, the firm earned ($1.46) EPS. On average, analysts expect that Ultragenyx Pharmaceutical will post ($7.14) earnings per share for the current year.
In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis bought 7,500 shares of the company’s stock in a transaction on Monday, August 28th. The shares were bought at an average cost of $52.52 per share, with a total value of $393,900.00. Following the completion of the acquisition, the chief executive officer now owns 430,569 shares of the company’s stock, valued at $22,613,483.88. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 9.20% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Ultragenyx Pharmaceutical (RARE) Receives Coverage Optimism Rating of 0.15” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/11/ultragenyx-pharmaceutical-rare-receives-coverage-optimism-rating-of-0-15.html.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.